Cancer Deaths Continue to Decline

What the Decline in Cancer Deaths Actually Means

According to the American Cancer Society’s 2026 estimates, the age-adjusted cancer mortality rate fell 34% between its 1991 peak and 2023. That decline translates into approximately 4.8 million fewer cancer deaths than would have occurred if the peak mortality rate had continued.

The phrase age-adjusted is important. The United States has a growing and aging population, and cancer becomes more common with age. Adjusting for age allows researchers to compare different years without mistaking demographic change for a change in cancer risk.

That also explains why a declining death rate can coexist with a largeor even increasingnumber of annual deaths. More Americans are reaching ages at which cancer is more likely, so the absolute number of cases can rise while the individual population-level risk of dying from cancer falls.

The Recent Trend Remains Encouraging

Federal cancer surveillance data show that overall cancer death rates declined steadily among both men and women from 2001 through 2022. During the more recent 2018–2022 period, mortality decreased by an average of about 1.7% per year among men and 1.3% per year among women.

Those percentages may look modest, but national health statistics are not a clearance sale. Even a one-percentage-point annual improvement, repeated across a population of hundreds of millions, represents thousands of people who remain alive to attend graduations, argue over thermostat settings, and complain that streaming services have too many menus.

Why Cancer Mortality Is Falling

1. Fewer People Are Smoking

The reduction in tobacco use is one of the biggest reasons cancer deaths have declined. Smoking is associated not only with lung cancer but also with cancers of the mouth, throat, esophagus, pancreas, kidney, bladder, cervix, colon, rectum, liver, and stomach, among others.

Lung cancer remains the leading cause of cancer death in the United States, yet its mortality rate has fallen substantially. Decades of cigarette taxes, smoke-free policies, public education, advertising restrictions, and smoking-cessation services have reduced tobacco exposure. Because cancer can take years to develop, today’s declining death rate partly reflects prevention decisions made many years ago.

There is also good news for people who currently smoke: quitting still matters. Risk does not disappear overnight, but it generally falls over time. The body, rather generously, does not demand a perfect past before allowing a healthier future.

2. Screening Finds Some Cancers Earlier

Screening can identify certain cancers before symptoms appear, when treatment is often more effective. Mammography can detect breast tumors at earlier stages. Low-dose computed tomography can identify lung cancer in eligible high-risk adults. Cervical screening can find abnormal cells before they become invasive cancer.

Colorectal screening can do something especially useful: it may prevent cancer altogether by finding and removing precancerous polyps. Colonoscopy is one option, but stool-based tests and other approved approaches can also help increase participation. The best screening test is generally the appropriate one that a patient can access, complete, and follow up correctlynot the one that spends six months decorating a bathroom shelf.

Screening is not automatically beneficial for every person or every cancer. Eligibility depends on age, health, family history, previous results, and individual risk. Patients should discuss current recommendations with a qualified healthcare professional rather than ordering a full-body scan because an online advertisement featured an unusually confident person wearing a white coat.

3. Cancer Treatment Has Become More Precise

Traditional cancer treatment relied heavily on surgery, radiation, and chemotherapy. These approaches remain essential, but they are now joined by targeted therapies, immunotherapies, hormone treatments, antibody-drug conjugates, cellular therapies, and increasingly sophisticated combinations.

Targeted therapies act on specific mutations, proteins, or biological pathways that help a tumor grow. Molecular testing can therefore divide what once looked like one disease into multiple subtypes. Two people with lung cancer, for example, may receive very different treatments based on the genetic features of their tumors.

Immunotherapy helps the immune system recognize or attack cancer more effectively. It has produced long-lasting responses for some patients with melanoma, lung cancer, kidney cancer, bladder cancer, and several other malignancies. It is not a universal cure, and side effects can be serious, but it has changed the outlook for groups of patients who previously had limited options.

4. Care Around the Treatment Has Improved

Progress is not limited to tumor-shrinking drugs. Better imaging, radiation planning, surgical techniques, infection control, anti-nausea medications, pain management, blood-product support, nutrition services, and symptom monitoring allow more patients to complete effective treatment safely.

Multidisciplinary care has also become more common. Surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, genetic counselors, nurses, pharmacists, and palliative-care specialists can coordinate decisions rather than treating a complicated disease as a relay race in which someone misplaced the baton.

Which Cancers Are Driving the Improvement?

Much of the overall reduction in cancer mortality has come from progress against four common cancers: lung, colorectal, female breast, and prostate cancer.

• Lung cancer: Reduced smoking, expanded high-risk screening, improved surgery, targeted drugs, and immunotherapy have contributed to declining mortality.
• Colorectal cancer: Screening, polyp removal, earlier detection, better surgery, and modern drug combinations have reduced deaths, particularly among older adults.
• Breast cancer: Mammography, hormone therapy, HER2-targeted treatments, genomic testing, and improved chemotherapy have increased the number of long-term survivors.
• Prostate cancer: Earlier detection, better risk classification, advances in radiation and surgery, hormone-based treatment, and newer systemic therapies have improved outcomes.

Other striking gains have occurred in melanoma, where immunotherapy and targeted treatment have transformed care for many patients with advanced disease. Mortality has also declined for several blood cancers as stem-cell transplantation, precision medicines, antibodies, and cellular therapies have improved.

Children have benefited as well. National data indicate that overall cancer death rates among children ages 0 to 14 declined by an average of roughly 1.5% per year from 2001 through 2022. Childhood cancer remains devastating, but modern risk-based treatment has turned several once-deadly diagnoses into highly treatable diseases.

Why This Is Not Yet a Victory Lap

Incidence Is Rising for Several Cancers

While cancer deaths continue to decline overall, diagnoses are increasing for several common malignancies. Recent reports have highlighted rising incidence of breast, prostate, pancreatic, uterine, oral-cavity, and certain liver cancers, as well as melanoma among women.

Colorectal cancer is another concern because incidence has been increasing among adults younger than 50. Researchers are studying possible contributors, including obesity, diet, metabolic health, environmental exposures, changes in the gut microbiome, and other factors. No single explanation has closed the case.

Pancreatic cancer remains particularly difficult because it often causes few recognizable symptoms before reaching an advanced stage. Effective population-wide screening is not currently available for average-risk adults, and survival remains far lower than it is for many common cancers.

Progress Is Not Shared Equally

National averages can hide major differences by race, income, geography, insurance status, disability, and access to specialized care. Black Americans, for example, continue to experience a higher overall cancer mortality rate than White Americans, although the gap has narrowed substantially over time.

American Indian and Alaska Native communities face high burdens from several preventable or treatable cancers. Rural patients may have to travel long distances for radiation, clinical trials, genetic counseling, or high-volume surgery. Uninsured and underinsured patients may delay screening or face interruptions in treatment because cancer apparently did not receive the memo that medical bills should be less complicated.

A scientific breakthrough cannot reduce mortality if the people who need it cannot obtain it. Transportation, paid leave, childcare, language services, insurance coverage, culturally responsive care, and affordable medication are therefore part of cancer controlnot optional accessories.

How More Cancer Deaths Can Be Prevented

Researchers estimate that a substantial proportion of U.S. cancers are associated with modifiable risk factors. Individual choices matter, but healthy choices must also be realistic and accessible. A neighborhood without safe places to exercise, affordable nutritious food, clean air, or nearby medical care is not offering residents an equal set of options.

Practical Steps That Make a Difference

• Avoid tobacco and seek professional help to quit smoking or using other tobacco products.
• Discuss recommended breast, cervical, colorectal, lung, and prostate cancer screening with a healthcare professional.
• Receive HPV and hepatitis B vaccination when eligible, since these vaccines can prevent infections associated with cancer.
• Limit alcohol, protect skin from excessive ultraviolet exposure, and avoid indoor tanning.
• Stay physically active and work toward a sustainable body weight without treating the bathroom scale like a courtroom judge.
• Learn about significant family cancer history and ask whether genetic counseling is appropriate.
• Report persistent or unexplained changessuch as unusual bleeding, a new lump, unexplained weight loss, or a lasting change in bowel habitsto a medical professional.

These measures reduce risk; they do not guarantee immunity. People who live healthfully can still develop cancer, and a diagnosis is never evidence of personal failure. Biology is complicated, environmental exposures are uneven, and random cellular errors do not consult anyone’s fitness tracker.

What the Decline Feels Like in Everyday Life

The following are illustrative composite experiences based on common cancer-care pathways. They do not describe identifiable patients.

The Screening Appointment That Was Easy to Postpone

Consider a 58-year-old office manager who repeatedly delays colorectal screening. Work is busy, the family calendar resembles air-traffic control, and discussing stool tests ranks somewhere below cleaning the garage. After a primary-care visit, the patient completes a home screening test. An abnormal result leads to colonoscopy, where a localized tumor and additional precancerous polyps are found.

The cancer is removed surgically before it spreads to distant organs. Follow-up surveillance replaces months of intensive metastatic treatment. The experience is still frightening; “caught early” does not make surgery, pathology reports, or waiting-room coffee delightful. But early detection changes the range of available treatment and the likelihood of long-term survival. At the family level, a national mortality trend becomes something tangible: another birthday dinner with the same terrible jokes.

When Lung Cancer Is No Longer Treated as One Disease

Now imagine a former smoker diagnosed with advanced non-small cell lung cancer. A generation ago, treatment choices might have been limited and largely based on where the tumor began and how it looked under a microscope. Today, the oncology team orders molecular testing and identifies a targetable alteration.

The patient begins an oral targeted therapy instead of receiving the exact regimen that would be used for every similar-looking lung tumor. Follow-up scans show that the cancer has shrunk. Treatment brings fatigue and other side effects, and resistance may eventually develop, but the disease can sometimes be controlled for a meaningful period.

This experience captures an important reason lung cancer mortality has fallen faster: modern oncology increasingly asks not only, “Where did this cancer start?” but also, “What is driving it?” The answer can unlock treatment that did not exist when many current patients were children.

Survivorship Brings a Different Kind of Work

A third experience begins after treatment ends. A woman treated for early-stage breast cancer finishes surgery and radiation, then continues hormone therapy to reduce recurrence risk. Friends congratulate her for being “done,” but survivorship is not a light switch. She still manages joint discomfort, worries before follow-up imaging, and wonders whether every new ache deserves a phone call.

Her care plan includes surveillance, management of treatment effects, exercise support, and communication between oncology and primary care. Over time, appointments become less frequent. Cancer remains part of her history without occupying every room in her mental house.

Millions of avoided deaths create millions of experiences like these: people returning to work, raising children, caring for parents, adapting to lasting side effects, or living with cancer as a chronic illness. Declining mortality is not merely a cleaner line on a graph. It is extra ordinary timeand “ordinary” is doing heroic work in that sentence.

Conclusion

The continuing decline in U.S. cancer deaths is one of modern public health’s most meaningful achievements. Lower smoking rates, effective screening, earlier diagnosis, precision medicine, immunotherapy, improved surgery, and stronger supportive care have collectively prevented millions of deaths.

Yet the work is unfinished. Rising incidence among younger adults, stubbornly lethal cancers, unequal access to care, and persistent racial and geographic disparities could slow future progress. The next chapter will require more than new medicines. It will require prevention policies, affordable screening, diverse clinical research, timely diagnosis, and reliable access to high-quality treatment.

The headline is hopeful: cancer deaths continue to decline. The assignment is equally clearmake that progress faster, broader, and available to everyone.